ARS Pharmaceuticals, Inc. SPRY Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from ARS Pharmaceuticals, Inc.’s reported figures.
Based on the most recent quarter.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s debt-to-equity?
- ARS Pharmaceuticals, Inc. (SPRY) reported debt-to-equity of 1.6× in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s debt-to-equity changed year-over-year?
- ARS Pharmaceuticals, Inc.'s debt-to-equity increased by 524700.0% year-over-year, from 0× to 1.6×.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s debt-to-equity?
- Over 3 years (2022 to 2025), ARS Pharmaceuticals, Inc.'s debt-to-equity has grown at a 676.7% compound annual growth rate (CAGR), from 0× to 0.8×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.